|Day's range||4.1000 - 4.9200|
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $372.36, marking a +0.27% move from the previous day.
Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.
HERCULES, Calif., June 01, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 PM Eastern Time. The presentation will be followed by a Q&A session with participation from Bio-Rad’s Executive Vice President and CFO Ilan Daskal.
Today we're going to take a look at the well-established Bio-Rad Laboratories, Inc. ( NYSE:BIO ). The company's stock...
Bio-Rad Laboratories ( NYSE:BIO ) First Quarter 2023 Results Key Financial Results Revenue: US$676.8m (down 3.3% from...
HERCULES, Calif., May 08, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 3:35 PM Eastern Time (12:35 PM Pacific Time).
Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.
Bio-Rad (BIO) delivered earnings and revenue surprises of 3.09% and 0.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
HERCULES, Calif., May 04, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023.
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.
Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.
Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.
Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day.
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.
The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.